Arakion is pioneering bioinsecticides using peptides derived from arachnid venom to target insect ion channels with high selectivity. This innovative approach promises species-specific action and biodegradability, offering a novel alternative to traditional chemistries.
Arakion is at the forefront of developing next-generation bioinsecticides by leveraging peptides inspired by arachnid venom. These small, disulfide-stabilized peptides are designed to engage insect ion-channel targets with high selectivity, offering potential for species-specific action and biodegradability. This approach represents a novel alternative to traditional insecticides and Bt traits, tapping into under-explored sites of action within ion channels.
Currently at TRL 3, Arakion has identified promising peptide candidates and achieved millilitre-scale expression suitable for initial bioassays. Future validation plans include expanded expression, electrophysiology studies, and greenhouse trials to refine and prepare the technology for larger-scale deployment.
Arakion is an early-stage biotechnology startup that develops AI-powered bioinsecticides derived from arachnid venom. The company integrates artificial intelligence-based protein design with experimental validation and recombinant expression to create novel, peptide-based solutions. This approach aims to deliver precise and effective pest control options targeting high-value agricultural crops.
By leveraging AI-guided peptide design, Arakion seeks to provide farmers with safer and more selective alternatives to traditional pesticides. The company is focused on revolutionizing agricultural pest management by tackling critical pests with new modes of action, while prioritizing sustainability and scalability in its development pipeline.